Clinical Trial Update: Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension [Phase 3]

View source ↗

Summary

Phase 3 study of adjunctive ganaxolone in adults with drug-resistant partial onset seizures completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Drug-resistant Partial Onset Seizures

Drugs mentioned

• ganaxolone (ganaxolone)

Snippet

Sponsor: Marinus Pharmaceuticals | Conditions: Drug Resistant Partial Onset Seizure | Phase 3 | Status: COMPLETED | Results posted: 2023-02-14